UnitedHealth's strong track record of surpassing analyst EPS estimates underpins the 82.5% market-implied probability of a Q3 2026 beat ahead of the October 13 release. The company delivered a 22-29% EPS surprise in Q2 2026 and has beaten estimates in 93% of recent quarters, supported by raised full-year adjusted EPS guidance to $19.50–$20 following Medicare Advantage margin expansion above 3% and OptumHealth outperformance. Consensus EPS for the quarter sits near $4.12 amid revenue expectations around $111–112 billion, with recent estimate revisions reflecting sustained cost management and enrollment trends. While medical cost pressures in commercial segments introduce some variability, traders price in the elevated likelihood of another beat given the pattern of positive surprises and forward guidance momentum.